We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 610

IP Australia releases examination practice guidelines following D’Arcy v Myriad Genetics High Court decision
  • Davies Collison Cave
  • Australia
  • December 15 2015

Following the High Court of Australia’s decision in D’Arcy v Myriad Genetics Inc. (see our Report), IP Australia sought public consultation on how it


Trade Marks Office decides opposition evidence filed 1 week after deadline can be considered under regulation 21.19
  • Davies Collison Cave
  • Australia
  • August 27 2015

We previously reported that the new extension of time provisions to file evidence in trade mark oppositions introduced by the Intellectual Property


A possible silver lining for Australia’s biotech innovators after bombshell Myriad decision
  • Davies Collison Cave
  • Australia
  • October 22 2015

IP owners everywhere are well aware that a ruling on patent eligibility from a country's highest court can turn a market on its head overnight. As


IP Australia proposes sensible change to examination practice in response to Myriad High Court decision
  • Davies Collison Cave
  • Australia
  • October 22 2015

In the wake of the High Court of Australia decision in D'Arcy v Myriad Genetics Inc. (see our report) handed down on 7 October 2015 IP Australia has


Australia: a year in the Australian IP courts
  • Davies Collison Cave
  • Australia
  • October 23 2015

The High Court considers patentability issues and distinctiveness of foreign words, while the Federal Court considers unique preliminary discovery


An extended sigh of relief for Lundbeck - High Court holds that failure to make a timely application for pharmaceutical patent term extensions is not excluded from remedial provisions.
  • Davies Collison Cave
  • Australia
  • November 5 2014

The long running battle in relation to Lundbeck’s LEXAPRO has finally reached an end with the High Court’s majority (3:2) finding that remedial


Poisonous priority arrives in Australia and New Zealand
  • Davies Collison Cave
  • Australia, New Zealand
  • November 6 2014

The term, "poisonous priority", is a relatively recent term used to describe an unusual phenomenon encountered in Europe where a claim in a patent or


Trade Marks Office outlines relevant principles for objecting to trade marks containing inn stems
  • Davies Collison Cave
  • Australia
  • January 17 2013

A recent decision of the Australian Trade Marks Office will be welcomed by pharmaceutical companies seeking to register trade marks containing an INN


Australia legalises medicinal cannabis products and research
  • Davies Collison Cave
  • Australia
  • October 26 2016

The commencement of the Narcotic Drugs Amendment Act 2016 on 30 October, 2016 marks a milestone in health and medicine in Australia with the


TiVo successfully sets aside Deed of Company Arrangement entered into by Vivo
  • Davies Collison Cave
  • Australia
  • September 12 2014

In a decision handed down on 29 July 2014, Justice Gordon of the Federal Court held that a Deed of Company Arrangement (DOCA) entered into by Vivo